50th ERA-EDTA Congress - Press Release Fresenius Medical Care

Australia Newsletter Image 1

High Volume HDF improves patient survival

The Catalonian Online Haemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from haemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment. At this year’s ERA-EDTA Congress, HighVolumeHDF was the main focus of Fresenius Medical Care’s activities.

Click here to read more.

For more information about HighVolumeHDF, please visit the website by clicking here.

Source: www.fmc-ag.com